Signed a multi-year strategic partnership with OpenAI to embed generative AI and large language models across the entire value chain — from drug-target discovery to digital health solutions and commercial operations. The partnership places Novo at the forefront of AI transformation in pharma.

Invested $1 billion in Nvidia and launched an "AI Collaborative Innovation Lab." Operates LillyPod — a 1,016-GPU Nvidia supercomputer for end-to-end drug-program integration. Collaborating with Profluent to develop custom site-specific recombinases for hard-to-treat diseases.

Co-hosts the UK-based Cambridge-1 supercomputer with Nvidia, having trained AI on more than 1.4 billion compounds. Uses its QCS algorithm platform for patient selection in oncology. Collaborates with BenevolentAI and Qure.ai for CKD and pulmonary fibrosis targets. Reinvent program accelerates concept-to-lead-molecule speed.

Launched a "hybrid-cloud AI factory" with Nvidia deploying over 3,500 Blackwell GPUs across the US and Europe — the largest pharma GPU installation publicly disclosed. Topped Statista's AI readiness index in 2023. Partnered with Recursion Pharmaceuticals and established a dedicated AI hub after 25+ AI partnerships.

Integrates AI through partnerships with Tempus, CytoReason, and Gero across drug discovery, clinical trials, and patient population analysis. AI helped accelerate Paxlovid development, reducing computational time by 80–90%. CytoReason provides an AI model of the immune system.

Janssen runs 100+ AI projects via the Trials360.ai platform. The Mulund plant in India (WEF Lighthouse) uses AI/ML for predictive maintenance (50% less unplanned downtime) and smart demand forecasting (OTIF +4.5 pts). A benchmark for AI-driven manufacturing excellence.

Running 150+ AI projects across the enterprise. Partners with Microsoft and Nvidia to scale AI over a decade. Collaborates with BenevolentAI for drug discovery targets, aiming to improve access, reduce costs, and improve health outcomes broadly.

Early adopter of Nvidia BioNeMo, using it to build Freyja — a proprietary generative AI model for analyzing large human datasets. Freyja supports target identification and molecule design across Amgen's therapeutic areas.

Partnered with Exscientia on three AI-driven small-molecule programs in cardiovascular and oncology. Exscientia may receive up to €240 million in payments. The alliance blends Exscientia's AI platform with Bayer's drug development expertise to accelerate lead discovery.

CEO targets a 50% reduction in time to select targets and design molecules. Already using AI to streamline clinical operations and quality oversight, with a goal of 30% reduction in cycle times. Signed a deal with Faro to scale AI-powered clinical trial workflows.

Advantage AI program anchors partnerships with Cloud Pharmaceuticals and Insilico Medicine for target identification, drug design, and lead generation. Pursuing AI across R&D and commercial functions through a structured multi-partner strategy.

Developed the "plai" AI platform with Aily Labs to aggregate internal data for decision-making across drug development, clinical trials, and manufacturing. Also partners with Hillo for AI-powered connected insulin pens and joined industry blockchain initiative PharmaLedger.

Indore facility (WEF Lighthouse) reduced changeover durations by 22% through AI-driven job shop scheduling. Full supply chain visibility and intelligent automation also cut manufacturing costs by 26%, demonstrating strong regional AI manufacturing leadership.

Partnered with Imagene AI (USA) to advance biomarker discovery and treatment response prediction across its oncology pipeline. Represents Japan's growing AI pharma investment, bridging domestic R&D with global AI specialists.

Partnered with German innovation hub BioMed X to launch its first France-based research team at Paris-Saclay, focused on AI-driven antibody engineering. Targets next-generation biologic design through the collaboration.